It was the best of interviews, it was the worst of interviews. At times I was born aloft on the wings of enlightenment, other times I feared I would drown in a sludge of foolishness. On the one hand ...
Exploring Teclistamab’s Potential in Combination Therapy for Multiple Myeloma: Marc S. Raab, MD, PhD
Marc S. Raab, MD, PhD, discusses the different ways that combination therapy that includes teclistamab can benefit patients ...
Many times I doubt if our armed forces are serious about wanting indigenous equipment; they seem to delay until they can ...
The winner of a 2025 SITC grant examines mechanisms that may help explain why drugs that work for some forms of lymphoma ...
Floyd Brink was appointed as Johannesburg city manager for the second time on Thursday. According to the recommendations at ...
Adam Sadilek is the Founder and CEO of AIM. As a kid, he was obsessed with robotics and automation—driven by a desire to build systems that learn on their own and make physical work smarter, faster, ...
In the first part of this interview, Romanski tells PharmTech Group that while the field of oral dosage forms has not grown ...
Sequoia's managing partner Roelof Botha defended his colleague's controversial comments that sparked an online backlash, ...
Kirsty McGhee did a PhD in condensed-matter physics at the University of Sheffield, UK, and a postdoc at the University of Leipzig, Germany, before becoming a science writer at the quantum-software ...
React4Life’s Silvia Scaglione emphasizes how organ-on-chip tech and AI are reshaping drug testing, personalized treatment, ...
Hanno Lustig is the Mizuho Financial Group Professor of Finance at the Stanford Graduate School of Business and a Senior ...
Shared biological, psychological, and social pathways put patients at risk for both, whether obesity or depression occurs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback